EU review extended for marketing authorisation application for haemophilia A gene therapy Valrox (valoctocogene roxaparvove)

The company disclosed in a US Securities and Exchange Commission filing that European Medicines Agency has asked for full 52-week results from 134 patients taking part in ongoing phase III study and potential submission of data is anticiparted by end of first quarter of 2021.

PharmaTimes